Phase I Studies Clause Samples

The 'Phase I Studies' clause defines the requirements and parameters for conducting initial clinical trials, typically focused on assessing the safety, tolerability, and pharmacokinetics of a new drug or treatment in a small group of healthy volunteers or patients. This clause outlines the scope of the studies, the responsibilities of the parties involved, and any regulatory or ethical considerations that must be met before proceeding. Its core practical function is to ensure that the foundational safety data is collected in a controlled manner, thereby minimizing risk and establishing a basis for further clinical development.
Phase I Studies. BPM shall keep Roche informed and consult with Roche as needed through the JDC on the progress of Phase I Studies conducted by BPM.
Phase I Studies. When the last Phase I study relating to the first SansRosa Product is clinically complete, and CollaGenex has determined that the results of the Phase I studies support a decision to move on to Phase II studies, CollaGenex shall purchase, and the Shareholders shall deliver to CollaGenex, 10% of the Shares at a price per share that results in the amount of aggregate consideration payable at such time being $[**].
Phase I Studies. The drug was administered to normal volunteers in single (25-500mg) and multiple (25-250mg) dose studies. Findings are summarized here.